AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02152995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine I 124
Description: Undergo iodine I-124 PET/CT
Study NCT02152995 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I-131
Description: Given PO
Study NCT02397395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV) 150 mg
Description: Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
Study NCT02397395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60 mg
Description: Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
Study NCT03129334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LST Middle School Online
Description: The adapted intervention will (1) utilize both online e-learning module (self-guided) and classroom-based sessions (facilitator led) to address PDA and concurrent ATOD abuse; (2) positively change social norms and challenge positive expectancies regarding PDA and ATOD abuse; (3) discourage diversion of prescription medications; (4) enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios; and (5) incorporate booster sessions.
Study NCT00360282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: In an unlabeled pill given once on one of two visits.
Study NCT04425083 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04450615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: The exercise protocol consists of the following sets and repetitions, with a total duration of 5 weeks and a frequency of 3 sessions per week.~Dynamic exercises: 2 sets of 10 to 15 repetitions (each side) Isometric exercises: 2 sets of 5 to 15 seconds (each side) Week 1- As mentioned above Week 2- Add 1 set Week 3 - Add 5 seconds and 5 repetitions Week 4 - Add 1 set Week 5- Add 5 seconds and 5 repetitions
Study NCT00880932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Alert
Study NCT04419493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase (from modified manufacturing process)
Description: Alteplase, TPA-05
Study NCT04419493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase (from current manufacturing process)
Description: Alteplase, TPA-02
Study NCT04419493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Description: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Study NCT04419493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Description: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Study NCT03399734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Single oral dose of 1 x 4-mg perampanel tablet
Study NCT03399734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Single 4-mg dose of perampanel fine granules
Study NCT03726905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory muscles training
Description: 4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time
Study NCT03726905 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham respiratory muscles training
Description: 4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
Study NCT03726905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: 12 weeks treadmill walking
Study NCT03726905 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: aerobic training
Description: 12 weeks treadmill walking
Study NCT04711564 — intervention group
Intervention type: OTHER
Intervention: Olive oil-based intravenous fat emulsions
Description: Parenteral nutrition planned according to the requirements of the patients is given for ten days.
Study NCT04711564 — intervention group
Intervention type: OTHER
Intervention: Soybean-based intravenous fat emulsions
Description: Parenteral nutrition planned according to the requirements of the patients is given for ten days.
Study NCT00993447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous at Day 0, 6 and 12 months
Study NCT00993447 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
Description: NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
Study NCT04218929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Formula (SF)
Description: New infant formula for term infants fed ad lib
Study NCT04218929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Formula (CF)
Description: Commercially available infant formula for term infants fed ad lib
Study NCT01957189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride and Tamsulosin
Description: 0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
Study NCT03285282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolumber interfascial plane block
Description: Thoracolumber interfascial plane block versus placebo
Study NCT03082963 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electrogram Morphology Mapping (EMR)
Description: Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium \& then the left atrium.
Study NCT03551015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in the timing of components of usual care
Description: Bringing forward outpatient review, and cardiac rehabilitation after CABG by 3 and 4 weeks respectively.
Study NCT00970502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib + celecoxib
Description: In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
Study NCT00655187 — intervention group
Intervention type: OTHER
Intervention: Collection of information
Description: Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
Study NCT00655187 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of stool samples
Description: Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
Study NCT01794325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trans-radial
Description: Coronary angiography performed through trans-radial access
Study NCT02097368 — intervention group
Intervention type: PROCEDURE
Intervention: swallowing tests
Description: swallowing tests
Study NCT02097368 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging
Study NCT01794325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trans-femoral
Description: Coronary angiography performed through trans-femoral access
Study NCT02576574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
Study NCT02576574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants received Pemetrexed 500 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
Study NCT02576574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants received Paclitaxel 200 mg/m\^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
Study NCT02576574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants received Gemcitabine 1250 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
Study NCT02576574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants received Gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
Study NCT04564040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment A
Description: Participants will receive 100 mg AT suspension in water via NG tube.
Study NCT04564040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment B
Description: Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.
Study NCT04564040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment C
Description: Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.
Study NCT04564040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment D
Description: Participants will receive 100 mg AT orally.
Study NCT02576574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
Study NCT02556632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin-based Gel
Description: Applied topically
Study NCT02556632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermatologic Complications Management
Description: Apply HPR Plus topically
Study NCT02556632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02556632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02556632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Apply placebo gel topically
Study NCT02556632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02556632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01732198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NU300
Study NCT01732198 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB
Study NCT01732198 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Study NCT01732198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Study NCT02152995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02152995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies
Study NCT02152995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo iodine I-124 PET/CT
Study NCT02152995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT04494282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic retrograde pancreatography
Description: Endoscopic cannulation of main pancreatic duct
Study NCT04128878 — intervention group
Intervention type: DRUG
Intervention: Sotalol
Description: The primary goal of the study will be to evaluate the change in endothelial function seen after initiating anti-arrhythmic medical therapy. Testing will be performed at baseline prior to the 1st dose of anti-arrhythmic therapy and again 1-3 months later at outpatient follow-up visit. We will record the resting flow (RF), biological zero (BZ) and peak flow (PF) as perfusion units (PU). Specifically, we will assess arterial stiffness and vasodilation in response to acetylcholine iontophoresis, nitroprusside iontophoresis, local thermal hyperemia and reactive hyperemia. Laser speckle contrast imaging will be employed to evaluate the microvasculature. SphygmoCor (arterial tonometry) will be used to assess macrovasculature.
Study NCT04128878 — intervention group
Intervention type: DRUG
Intervention: Dofetilide
Description: Same as described above with sotalol.
Study NCT01255579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol Fluticasone
Description: salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
Study NCT01255579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol - beclometasone
Description: formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
Study NCT02261675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
Study NCT00795977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cells, OK-432
Description: Single Group Assignment
Study NCT02948205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D group
Description: infertility patient get TU-LESS by 3D Laparoscopy
Study NCT02572973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic Neuromodulation (ANM)
Description: The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
Study NCT02572973 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acoustic Neuromodulation (ANM)
Description: The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
Study NCT03523507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active: rTMS
Description: Daily sessions will consist of 3000 left-sided excitatory pulses at 10 Hz (with 4-second trains and 26-second inter-train interval) followed by 1000 right-sided inhibitory pulses at 1 Hz (in a single train). The DLPFC treatment target will be determined using individualized resting-state network mapping.
Study NCT03523507 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham: rTMS
Description: Daily sessions will consist of the same total number of sham pulses, designed to have similar sound and tactile sensation, without producing active stimulation.
Study NCT02576574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants received Cisplatin 75 mg/m\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
Study NCT02576574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 mg/mL\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
Study NCT02576574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Weekly
Description: Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
Study NCT00870805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral ultrabrief ECT
Description: Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
Study NCT00870805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral standard ECT
Description: Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
Study NCT00870805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: right-unilateral ultrabrief ECT
Description: Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
Study NCT00870805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right-unilateral standard ECT
Description: Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
Study NCT00968396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
Study NCT00968396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Co-culture Stem Cell Infusion on Day 0.
Study NCT00547391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
Study NCT00547391 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no intervention
Description: No intervention (controls). Follow up started from the day of randomization.
Study NCT00968396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 IV over 30 minutes daily on Days -2 and -1
Study NCT04610073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive multimedia training and illustrated booklet
Description: The experimental groups conducted interactive multimedia training and illustrated booklet
Study NCT01217528 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: device settings for group A
Description: VT zone: 350ms VF zone: 280ms
Study NCT01217528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device settings for group B
Description: VT zone: 320ms VF zone: 250ms
Study NCT04098068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
Study NCT04401579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching Baricitinib placebo contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating for the placebo tablet is identical to that of the corresponding active tablet.
Study NCT04401579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
Study NCT01917188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full simulation and education
Study NCT01917188 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: See simulation room, usual education
Study NCT00580333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
Study NCT00580333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
Study NCT00580333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Postoperative: Given intravenously for four 2-week cycles